Revance Therapeutics Investor Presentation — November 2020

Document content

COMPANY PRESENTATION

NOVEMBER 2020Daring To Make

COMPANY PRESENTATION

Forward -Looking Statements

Safe Harbor /Market Data

This presentation contains forward -looking statements, including forward -looking statements within the meaning of the Private Se curities Litigation Reform Act of 1995. These statements

relate to: financial metrics and outlook; the market size and growth of markets for global neuromodulators, dermal fillers an d aesthetics fintech platforms; the process and timing of, and

ability to complete, current and anticipated future clinical development of our investigational product candidates, including anticipated near -term milestones; statements about our ability

to obtain, and the timing relating to, regulatory submissions and approvals with respect to our drug product candidates and t he Teoxane’s RHA® Collection of dermal fillers, including with

respect to the anticipated approval of DaxibotulinumtoxinA for Injection in glabellar lines and the expected PDUFA date; our ability to successfully commercialize the RHA® Collection of

dermal fillers, the HintMD payments platform and our drug product candidates, if approved, and the timing of commercializatio n activities; our business strategy, timeline and other goals

and market for our anticipated products, plans and prospects, including our commercialization plans; development and commerci alization of a biosimilar to BOTOX®; royalty and milestone

payments from our commercial collaborations, including with Mylan; the benefits to customers of our product candidates and th e HintMD payments platform, including in comparison to

competitor offerings; and demand for our product candidates and drivers of demand.

These forward -looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Our expectations and beliefs regarding these matters

may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward -looking statemen ts as a result of uncertainties, risks and changes in

circumstances, including but not limited to risks and uncertainties related to: the results, timing, costs, and completion of our research and development activities and regulatory approvals,

including the potential delay in the anticipated PDUFA target action date for DaxibotulinumtoxinA for Injection for the treat men t of glabellar lines due to the inability of the FDA to complete

a manufacturing site inspection; the impact of the COVID -19 pandemic on our manufacturing operations, supply chain, end user dem and for our products, commercialization efforts,

business operations, clinical trials and other aspects of our business; our ability to manufacture supplies for our product c and idates and to acquire supplies of the RHA® Collection of dermal